Intravenous administration of 1 million of MSC
CeTMAd/ELA/2011
Phase 2 small_molecule completed
Quick answer
Intravenous administration of 1 million of MSC for Amyotrophic Lateral Sclerosis is a Phase 2 program (small_molecule) at Design Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Design Therapeutics
- Indication
- Amyotrophic Lateral Sclerosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed